

RealRate

PHARMACEUTICAL 2020

## BIOSPECIFICS TECHNOLOGIES CORP Rank 3 of 358







The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 375%, being 338% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	109,271
Cost of Goods Sold	0
Intangible Assets	573
Liabilities, Current	1,422
Liabilities, Non-Current	0
Other Assets	16,809
Other Compr. Net Income	0
Other Expenses	5,829
Other Liabilities	0
Other Net Income	1,987
Other Revenues	38,188
Property and Equipment	0
Research and Development	590
Selling, General and Administrative Expense	9,285

Output Variable	Value in 1000 USD
Assets	126,653
Liabilities	1,422
Expenses	15,705
Revenues	38,188
Stockholders Equity	125,231
Net Income	24,470
Comprehensive Net Income	24,470
Economic Capital Ratio	375%

